KeyBanc reiterates Lonza stock rating on strong modality positioning By Investing.com

FierceBiotechRare Disease Research, myTomorrows team up to help patients access trials

FierceBiotechAligos sells China rights to HBV drug to hepatology player Amoytop in $445M deal

FierceBiotechPfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial

FierceBiotechJohnson & Johnson hands back failed eye disease gene therapy to MeiraGTx

FierceBiotech'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once again

Thermo FisherThermo Fisher Scientific (TMO) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Promega BlogStolen Chloroplasts and the Chrysalis of Complex Life

IlluminaDRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows - PR Newswire

Lonza NewsKeyBanc reiterates Lonza stock rating on strong modality positioning By Investing.com - Investing.com Canada

BioWorldPerha Pharmaceuticals identifies new adenosine A3 receptor antagonists

BioWorldCogent Biosciences identifies new JAK2 V617F inhibitors

BioWorldCorbus Pharmaceuticals synthesizes new cannabinoid CB1 receptor antagonists or inverse agonists